Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Engensis (VM202) in Charcot-Marie-Tooth Disease Type 1A
NCT05361031Phase 2Completed
- Sponsor
- Helixmith
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Engensis in Charcot-Marie-Tooth disease type 1A (CMT1A), sponsored by Helixmith. Primary endpoint: Safety of Intramuscular Injections of Engensis at 270 days. Started Sep 2020; status: completed.
02
Drugs
Engensis
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)
Beyond the preview
Go deeper on NCT05361031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361031.